Amgen Inc. $AMGN Shares Bought by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5,554.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,693 shares of the medical research company’s stock after purchasing an additional 4,610 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Amgen were worth $1,324,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMGN. OLD National Bancorp IN increased its position in shares of Amgen by 296.2% in the second quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock valued at $5,027,000 after buying an additional 13,460 shares in the last quarter. Atlantic Union Bankshares Corp grew its stake in Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after acquiring an additional 6,627 shares during the period. L2 Asset Management LLC increased its holdings in Amgen by 50.8% in the 2nd quarter. L2 Asset Management LLC now owns 9,837 shares of the medical research company’s stock worth $2,747,000 after acquiring an additional 3,314 shares in the last quarter. Stephens Inc. AR increased its holdings in Amgen by 14.2% in the 2nd quarter. Stephens Inc. AR now owns 95,731 shares of the medical research company’s stock worth $26,729,000 after acquiring an additional 11,888 shares in the last quarter. Finally, CWM LLC raised its position in Amgen by 2.9% during the second quarter. CWM LLC now owns 154,418 shares of the medical research company’s stock worth $43,115,000 after acquiring an additional 4,306 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive clinical update — Amgen reported progress in its pediatric inebilizumab study, highlighting potential long‑term upside in a rare autoimmune indication that could expand future revenue and orphan pricing opportunities. Article Title
• Positive Sentiment: Pipeline durability — Amgen extended its long‑term pediatric psoriasis study for apremilast, signaling continued commitment to pediatric indications and increasing the value of its dermatology franchise. Article Title
• Positive Sentiment: Analyst sentiment supportive — Amgen received a consensus “Moderate Buy” from analysts, which can buoy inflows and help sustain multiple expansion given solid earnings and guidance history. Article Title
• Positive Sentiment: Included in “top drug stocks” narratives — industry write‑ups placing Amgen among big drugmakers positioned to outperform in 2026 raise visibility and may attract momentum investors. Article Title
• Positive Sentiment: Market performance note — coverage highlighting that Amgen is outpacing broader market gains reinforces a bullish technical/flow narrative among investors. Article Title
• Positive Sentiment: Index/leadership focus — commentary on Amgen’s biotechnology leadership and index positioning can support passive inflows and institutional demand. Article Title
• Neutral Sentiment: Competitive comparison — a sector piece comparing Novo Nordisk and Amgen frames AMGN more as a diversified biologics/pipeline play versus GLP‑1 leaders; useful for allocation decisions but not an immediate catalyst. Article Title
• Neutral Sentiment: Policy/deal with U.S. administration — reports that Amgen joined other firms in a drug‑pricing deal with the administration create mixed implications (pricing headwinds vs. tariff/incentive benefits and regulatory certainty). Investors will watch the net financial terms. Article Title

Amgen Stock Up 0.0%

Shares of NASDAQ:AMGN opened at $331.49 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The business has a fifty day moving average of $320.86 and a two-hundred day moving average of $300.89. The stock has a market cap of $178.50 billion, a P/E ratio of 25.62, a PEG ratio of 3.08 and a beta of 0.45. Amgen Inc. has a 52-week low of $257.05 and a 52-week high of $346.38.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Cantor Fitzgerald lifted their target price on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. Finally, DZ Bank boosted their price target on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $332.85.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last 90 days. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.